SOPH Share Price Performance
US$4.84
1.37 (39.54%)
30.9% undervalued intrinsic discount
US$7.00
Fair Value
Price US$4.84
AnalystConsensusTarget US$7.00
AnalystLowTarget US$6.00
AnalystHighTarget US$9.00
Fair ValueUS$7.00
Share Pricen/a
SOPHiA GENETICS SA Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
SOPH Community Narratives
AN
Fair Value US$7 30.9% undervalued intrinsic discount
Precision Medicine Advances Will Transform Global Healthcare Analytics
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$6 19.4% undervalued intrinsic discount
Revenue Lags And Margin Pressure Will Improve Eventually
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$9 46.3% undervalued intrinsic discount
AI Adoption And Global Precision Medicine Will Expand Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AI Adoption And Global Precision Medicine Will Expand Markets
Key Takeaways Rapid enterprise and pharma adoption, along with high-value applications, is driving significant recurring revenue growth, margin expansion, and a stronger competitive moat. Enhanced operational efficiencies and global platform integration are accelerating profitability and cementing SOPHiA GENETICS as a central player in AI-powered genomics.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$9
46.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
25.64% p.a.
Profit Margin
8.77%
Future PE
66.65x
Price in 2028
US$11.35
Precision Medicine Advances Will Transform Global Healthcare Analytics
Key Takeaways Rapid platform adoption and high-value partnerships are fueling recurring revenue growth, expanding usage, and opening new verticals for SOPHiA GENETICS. Process efficiencies and automation are driving margin improvements and setting the company on a path toward profitability and greater operating leverage.Read more
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$7
30.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
21.39% p.a.
Profit Margin
8.77%
Future PE
57.44x
Price in 2028
US$8.82
Revenue Lags And Margin Pressure Will Improve Eventually
Key Takeaways Complex product implementations and milestone-based contracts are causing unpredictable revenue timing, complicating earnings visibility and delaying sales growth impacts. Foreign exchange pressures and high upfront operating expenses are constraining margin expansion, even as platform adoption and clinical partnerships accelerate.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
19.4% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
17.32% p.a.
Profit Margin
8.77%
Future PE
54.54x
Price in 2028
US$7.56
Trending Discussion
Recently Updated Narratives
AN
Revenue Lags And Margin Pressure Will Improve Eventually
Fair Value: US$6 19.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Adoption And Global Precision Medicine Will Expand Markets
Fair Value: US$9 46.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Precision Medicine Advances Will Transform Global Healthcare Analytics
Fair Value: US$7 30.9% undervalued intrinsic discount
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
SOPHiA GENETICS SA Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.11
- 67.52%
- -102.29%
- 78.4%
About SOPH
- Founded
- 2011
- Employees
- 423
- CEO
- WebsiteView website
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
